TY - JOUR
T1 - Hypoxia-inducible factors
T2 - Mediators of cancer progression and targets for cancer therapy
AU - Semenza, Gregg L.
N1 - Funding Information:
Work in the author's laboratory is supported by grants from the American Cancer Society, the Johns Hopkins Institute for Cell Engineering, the National Cancer Institute, and the Susan G. Komen Foundation. G.L.S. is the C. Michael Armstrong Professor at the Johns Hopkins University School of Medicine and an American Cancer Society Research Professor.
PY - 2012/4
Y1 - 2012/4
N2 - Hypoxia-inducible factors (HIFs) mediate adaptive physiological responses to hypoxia. In human cancers that are accessible for O 2 electrode measurements, intratumoral hypoxia is common and severe hypoxia is associated with increased risk of mortality. HIF activity in regions of intratumoral hypoxia mediates angiogenesis, epithelial-mesenchymal transition, stem-cell maintenance, invasion, metastasis, and resistance to radiation therapy and chemotherapy. A growing number of drugs have been identified that inhibit HIF activity by a variety of molecular mechanisms. Because many of these drugs are already FDA-approved for other indications, clinical trials can (and should) be initiated to test the hypothesis that incorporation of HIF inhibitors into current standard-of-care therapy will increase the survival of cancer patients.
AB - Hypoxia-inducible factors (HIFs) mediate adaptive physiological responses to hypoxia. In human cancers that are accessible for O 2 electrode measurements, intratumoral hypoxia is common and severe hypoxia is associated with increased risk of mortality. HIF activity in regions of intratumoral hypoxia mediates angiogenesis, epithelial-mesenchymal transition, stem-cell maintenance, invasion, metastasis, and resistance to radiation therapy and chemotherapy. A growing number of drugs have been identified that inhibit HIF activity by a variety of molecular mechanisms. Because many of these drugs are already FDA-approved for other indications, clinical trials can (and should) be initiated to test the hypothesis that incorporation of HIF inhibitors into current standard-of-care therapy will increase the survival of cancer patients.
UR - http://www.scopus.com/inward/record.url?scp=84859445000&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84859445000&partnerID=8YFLogxK
U2 - 10.1016/j.tips.2012.01.005
DO - 10.1016/j.tips.2012.01.005
M3 - Review article
C2 - 22398146
AN - SCOPUS:84859445000
SN - 0165-6147
VL - 33
SP - 207
EP - 214
JO - Trends in Pharmacological Sciences
JF - Trends in Pharmacological Sciences
IS - 4
ER -